T1	Participants 34 66	patients with advanced melanoma:
T2	Participants 325 376	previously treated patients with advanced melanoma.
T3	Participants 470 518	enrolled patients without regard to HLA subtype.
T4	Participants 580 616	class-I HLA-A*0201-positive patients
T5	Participants 790 808	93.5% of patients.
T6	Participants 932 951	pretreated patients
T7	Participants 1155 1183	HLA-A*0201-negative patients
T8	Participants 1330 1362	137 HLA-A*0201-positive patients
T9	Participants 1712 1739	ipilimumab-treated patients
